TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03258515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
Study: NCT02712359

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection
Description: A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection
Description: A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection
Description: A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample collection
Description: A blood sample (\~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10).
Study: NCT00577031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2 iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: 1000mg/m2 po bid on days 1-14 of each 3 week cycle
Study: NCT04273659

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulses and cereals
Description: Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulses and cereals
Description: Dietary intervention. Ingestion of pulses with cereals and gastrointestinal health.
Study: NCT02001038

Intervention type: OTHER
Intervention: Survey
Study: NCT01204606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with intraoperative periarticular injection
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arthroscopic rotator cuff repair with non-injection of MMA drugs
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4 or 5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repaired of rotator cuff tear was done with suture anchors.~* 43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.~* Peripheral intravenous PCA(Patient Controlled Analgesia) was connected.
Study: NCT01439776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: 800IU/day
Study: NCT02751372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987517
Description: 50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated Skin
Description: This site is patched without treatment as irradiated control
Study: NCT00733642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 1 mg/kg
Description: PF-04360365 1 mg/kg infused as a single dose
Study: NCT03928483

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified WW Food program
Description: Participants will receive a structured, holistic, behavioral weight management program that encourages development of healthy habits to help individuals eat healthier, move more, and shift to a more helpful mindset.
Study: NCT03376724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Exercise Protocol
Description: Functional exercise protocol. This protocol started with corporal conscience exercise, breathing, abdominal activation, activities such as sitting, getting up, climbing stairs, reaching with arms, moving forward, bodyweight exercises, bridges and boards. This protocol will be performed during 12 weeks, two sessions per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal
Description: Analgesic use when necessary and a single back scholl class

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal
Description: Analgesic use when necessary and a single back scholl class
Study: NCT01172691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Description: iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
Study: NCT02837536

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal iCare
Description: IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal iCare
Description: IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vertical iCare
Description: IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vertical iCare
Description: IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
Study: NCT00850200

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Plan
Description: Between 21-39.6 Gy/CGE to the PTV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Photon Radiation Plan
Description: Between 21-39.6 Gy/CGE to the PTV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Plan
Description: Between 21-39.6 Gy/CGE to the PTV
Study: NCT00733642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 3 mg/kg
Description: PF-04360365 3 mg/kg infused as a single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 5 mg/kg
Description: PF-04360365 5 mg/kg infused as a single dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04360365 10 mg/kg
Description: PF-04360365 10 mg/kg infused as a single dose
Study: NCT03597126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted surgery
Description: robot-assisted intersphincteric resection for low location rectal cancer(T=1\&2)
Study: NCT02234908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contacts
Description: Household contacts who come to the study clinic, present a referral card, and complete TB symptom screening will receive a shopping voucher of $5-10 value.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Index
Description: Index subjects will be entered in a prize lottery if any of their contacts complete TB symptom screening at the study clinic.
Study: NCT00333112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tamsulosin
Description: oral
Study: NCT03597126

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic surgery
Description: laparoscopic intersphincteric resection for low location rectal cancer(T=1\&2)
Study: NCT00666328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clevidipine
Description: Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.~Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours.
Study: NCT00333112

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral
Study: NCT04430959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Candesartan 4 mg, tablets, orally, once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan
Description: Candesartan 4 mg, tablets, orally, once daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Candesartan placebo-matching tablets, orally, once daily for 4 weeks
Study: NCT02621528

Intervention type: DEVICE
Group type: OTHER
Intervention: CeraFlex
Description: The Lifetech CeraFlex™ study is a triple-arm study.
Study: NCT01277172

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV every 2 weeks for 6 cycles
Study: NCT01420302

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nurse directed
Description: Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LOGIC-Insulin
Description: Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
Study: NCT02711800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Description: The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
Study: NCT00839839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oocyte Vitrification
Description: All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
Study: NCT00003255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT03611725

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial artery
Description: The distal radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Radial artery
Description: The radial artery will be punctured with a puncture needle. Then, coronary angiography and percutaneous coronary intervention will be performed.
Study: NCT04805307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMG901
Description: CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMG901
Description: CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMG901
Description: CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT04430959

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Candesartan placebo-matching tablets, orally, once daily for 4 weeks
Study: NCT01277172

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 IV every 2 weeks for 6 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV every 2 weeks for 6 cycles
Study: NCT02565745

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Skin dressing
Description: Pre-determined skin areas at risk for PUs (3 or more, depending on the prevaliing body position, prone, supine or Sims') will be covered. Dressings will be changed every 6-7 days unless found wet/contaminated
Study: NCT04805307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMG901
Description: CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMG901
Description: CMG901 will be administered intravenously (IV) on Day 1 of every 21-day cycle. Individual subjects may continue study treatment until there is evidence of disease progression (clinical or radiologic) judged by Investigators, unacceptable toxicity or other reasons for treatment discontinuation.
Study: NCT01277172

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m2 IV every 14 days for 6 cycles
Study: NCT04433260

Intervention type: OTHER
Intervention: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index
Description: The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months
Study: NCT04865497

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.
Study: NCT04433260

Intervention type: OTHER
Intervention: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index
Description: The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months

Intervention type: OTHER
Intervention: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index
Description: The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months

Intervention type: OTHER
Intervention: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index
Description: The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months

Intervention type: OTHER
Intervention: Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index
Description: The electronic survey for phase 1 detailing questions regarding affective symptoms, behaviour and ongoing concerns will be sent and implied consent assumed from responders. A proportion of these patients who give consent to be repeatedly contacted throughout the study period will be recruited into phase 2 of the study at 6 weeks and 4 months

Intervention type: OTHER
Intervention: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.
Description: Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.

Intervention type: OTHER
Intervention: Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too.
Description: Follow-up electronic surveys including questions regarding affective symptoms, behavioural changes and mental well-being will be sent at 6-weeks and 4-months following the initial survey. This will be sent to participants from Groups 1-3 that provided consent to receive these follow-up questionnaires.
Study: NCT04865497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg adjuvant-free S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Haemophilus b Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus b Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus b Conjugate Vaccine
Description: Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg Haemophilus b Conjugate Vaccine.